Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto de Lima Lopes

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Breast (Edinburgh, Scotland)|December 6, 2019
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in TaiwanVakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, et al.
Data in Brief|February 20, 2020
Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare settingVakaramoko Diaby, Ching-Yu Wang, Hussain Alqhtani, et al.
Immunotherapy|August 4, 2016
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerPedro N Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, et al.
Einstein (Sao Paulo, Brazil)|July 9, 2015
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011Cinthia Leite Frizzera Borges Bognar, Sergio Daniel Simon, Rene Claudio Gansl, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2014
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysisAlexandre Chan, Hoon-Kyo Kim, Ruey Kuen Hsieh, et al.
Cancer|October 29, 2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trialsRanjan Pathak, Gilberto De Lima Lopes, Han Yu, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Future Oncology (London, England)|August 24, 2016
Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysisPedro Nazareth Aguiar, Hakaru Tadokoro, Gislaine Fernandes da Silva, et al.
JAMA Network Open|May 30, 2024
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung CancerSamuel A Kareff, Sunwoo Han, Benjamin Haaland, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Breast (Edinburgh, Scotland)|December 6, 2019
A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in TaiwanVakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, et al.
Data in Brief|February 20, 2020
Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare settingVakaramoko Diaby, Ching-Yu Wang, Hussain Alqhtani, et al.
Immunotherapy|August 4, 2016
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerPedro N Aguiar, Ilka Lopes Santoro, Hakaru Tadokoro, et al.
Einstein (Sao Paulo, Brazil)|July 9, 2015
The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011Cinthia Leite Frizzera Borges Bognar, Sergio Daniel Simon, Rene Claudio Gansl, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 13, 2014
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysisAlexandre Chan, Hoon-Kyo Kim, Ruey Kuen Hsieh, et al.
Cancer|October 29, 2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trialsRanjan Pathak, Gilberto De Lima Lopes, Han Yu, et al.
American Journal of Clinical Oncology|February 7, 2012
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancerPeter J Hosein, Gilberto de Lima Lopes, Vitor H Pastorini, et al.
Future Oncology (London, England)|August 24, 2016
Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysisPedro Nazareth Aguiar, Hakaru Tadokoro, Gislaine Fernandes da Silva, et al.
JAMA Network Open|May 30, 2024
International Cost-Effectiveness Analysis of Durvalumab in Stage III Non-Small Cell Lung CancerSamuel A Kareff, Sunwoo Han, Benjamin Haaland, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.
Pageof 8